Home > Insider Trading > Filing (0001140361-10-047771)

Filing Details

Accession Number:: 0001140361-10-047771
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-12-02 15:04:58
Reporting Period:: 2010-11-30

Filing Date:: 2010-12-02
Accepted Time:: 2010-12-02 15:04:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1375247	Obagi Medical Products Inc.	OMPI	Pharmaceutical Preparations (2834)	954658730

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1047028	P L Fund 1994 Appreciation Capital Stonington	600 Madison Avenue New York NY 10022		No	No	Yes	No
1047030	Stonington Partners Inc Ii	600 Madison Ave. New York NY 10022		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2010-11-30	2,688,668	$9.84	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

The record holder of such shares is Stonington Capital Appreciation 1994 Fund, L.P. (the "Stonington Fund").The Stonington Fund is a Delaware limited partnership whose limited partners consist of certain institutional investors, formed to invest in corporate acquisitions organized by Stonington Partners, Inc. Stonington Partners, L.P., a Delaware limited partnership, is the general partner in the Stonington Fund with a 1% economic interest. Except for such economic interest, Stonington Partners, L.P. disclaims beneficial ownership of the shares set forth above. Stonington Partners, Inc. II is the general partner of, with a 1% interest in, Stonington Partners, L.P. Except for such economic interest, Stonington Partners, Inc. II disclaims beneficial ownership of the shares set forth above. Pursuant to a management agreement with the Stonington Fund, Stonington Partners, Inc. has full discretionary authority with respect to the investments of the Stonington Fund, including the authority t
The Stonington Fund sold such shares to Obagi Medical Products, Inc. (the "Company") in accordance with the terms of a Stock Purchase Agreement, dated as of November 15, 2010, by and among the Company, the Stonington Fund and the other selling stockholder signatory thereto.
Such total also reflects the sale by the Stonington Fund of 2,033,617 shares of the Company's common stock in November 2010 pursuant to a registration statement on Form S-1 that was filed with the Securities and Exchange Commission (the "SEC") on October 26, 2010 and declared effective by the SEC on November 15, 2010. Such sale was exempt from the reporting requirements of Section 16(a) under the Securities Exchange Act of 1934, as amended, pursuant to Rule 16a-7 promulgated thereunder.